Anika Therapeutics sees FY25 adjusted EBITDA down 3% to up 3%

Anika expects updated 2025 revenue ranges by segment as follows: Commercial Channel, unchanged, of $47 to $49.5 million, up 12% – 18% year-over-year; OEM Channel of $62 to $65 million, down 16% – 20% year-over-year, as a result of lower forecasts on end user pricing from J&J MedTech as compared to our prior range of down 12% – 18% year-over-year. The Company is updating its guidance for Adjusted EBITDA to -3% to 3%, previously 8% to 10%, as a result of lower end-user pricing for Monovisc and Orthovisc, lower first half manufacturing yields, the costs for the Cingal bioequivalence study, and the known impacts associated with recently announced tariffs.